Skip to search formSkip to main contentSkip to account menu

Tafinlar

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BackgroundThe use of molecularly targeted therapy is becoming widespread in oncology. These agents cause tumour-specific genetic… 
Highly Cited
2016
Highly Cited
2016
This analysis presents anticancer drug combinations that contain two or more targeted agents and discusses their impact on… 
Review
2016
Review
2016
The RAS-RAF-MEK1/2-ERK1/2 pathway is a key signal transduction pathway in the cells. Critically, it remains constitutively active… 
2016
2016
Dabrafenib (Tafinlar) was approved in 2013 by the FDA as a selective single agent treatment for patients with BRAFV600E mutation… 
2015
2015
Despite the continuously increasing incidence of melanoma, over decades the therapy has barely changed. However, since 2011 the… 
2014
2014
Webster and Mentzer discuss the market landscape for malignant melanoma — a cancer for which treatment options have broadened… 
2014
2014
Dear Editor, Hairy cell leukemia (HCL) is a mature B-cell lymphoid cancer that can be treated successfully in the majority of… 
2013
2013
  • K. Garber
  • Nature biotechnology
  • 2013
  • Corpus ID: 205270372
On July 9, GlaxoSmithKline of London filed an application with the US Food and Drug Administration (FDA) seeking approval of BRAF…